規制動向

FDA、EMA、TGA および世界の規制動向

#Hikma Pharmaceuticals ×

2026年9月25日•1分で読めます

FDA Approves Lorazepam Injectable (ATIVAN) NDA018140

The FDA granted approval for NDA018140, authorizing Lorazepam injectable (brand name ATIVAN) from Hikma Pharmaceuticals USA and Civica, Inc.

2026年9月22日•1分で読めます

FDA Approves Buprenorphine ANDA078633 Sublingual Tablets

FDA has approved an ANDA for buprenorphine sublingual tablets (2 mg and 8 mg) from Hikma Pharmaceuticals USA Inc., with associated labeling and REMS submissions.

2026年9月15日•1分で読めます

FDA Approves Hikma Phenytoin Sodium Injection (ANDA 084307)

FDA has approved ANDA 084307 for Hikma Pharmaceuticals' generic phenytoin sodium injectable, available for intramuscular and intravenous use with multiple NDC listings.

2026年8月30日•1分で読めます

FDA Approves ANDA076330 for Octreotide Acetate Injection

The FDA has approved application ANDA076330 for octreotide acetate injectable products manufactured by Hikma Pharmaceuticals, available in two dosage strengths.